Imaging Glial Cells in Alzheimer’s Disease: From Light Microscopy to Multiplexed Ion Beam Imaging

Dunavan Morris-Janzen¹ and Dr. John Paul Oliveria²

¹Department of Medicine, Division of Respirology, McMaster University
²School of Medicine, Department of Pathology, Stanford University

INTRODUCTION

Alzheimer’s Disease (AD) is the leading cause of dementia worldwide, accounting for 60-70% of the nearly 50 million global cases of dementia in 2018 [1]. AD also significantly burdens Canadians, where the disease prevalence is 1,524 cases per 100,000 and incidence is 68 case per 100,000 [2]. The global societal costs of AD and dementia are estimated at $1 trillion dollars annually [1]. Furthermore, AD treatment options remain limited. All therapeutics targeted at decreasing production or increasing clearance of amyloid-β plaques, the characteristic AD biomarker, have thus far been unsuccessful in phase III clinical trials [1]. With such a significant burden of disease and no effective treatments, it is clear that AD research must elucidate the complex mechanisms underlying clinical progression in order for the disease to be better prevented, managed, and treated.

Since the 1980’s, researcher have understood AD through the amyloid cascade hypothesis (ACH). Specifically, the ACH postits that the clinical progression of AD is primarily caused by amyloid-β plaque deposits, tau aggregation in neurofibrillary tangles, and subsequent neuron death [3]. While the original ACH remains widely accepted in the field, new research has highlighted the key role of glial cells, primarily microglia and astrocytes, in AD pathogenesis [3]. It is now thought that the intricate interactions between microglia, astrocytes, and neurons becomes initially disturbed in early stages of the disease. As toxic amyloid-beta and hyperphosphorylated tau protein accumulation continues, these glial cells polarize towards an inflammatory phenotype that further contributes to neuron death [3]. However, research aimed at understand the complex interactions between tauopathy and amyloid-β accumulation, glial cell phenotypes, neuroinflammation, and neuron death, has been slowed by single-plex imaging technologies, and while they were able to make breakthrough discoveries, they were also limited by their imaging technologies which only permitted simultaneous visualization of one to two protein targets.

During the time that Alzheimer continued to research this new disease, the Carl Zeiss Company produced a novel microscopy technique known as fluorescence microscopy (FM), which uses ultraviolet light to excite fluorophores on target proteins to produce an image [6]. The principles of FM gave rise to IHC and immunofluorescence (IF) staining techniques. IHC and IF use antibody-antigen specificity to attach fluorophores to target antigens and cause light emission via enzymatic reactions or excitation, respectively. The advent of FM, as well as IHC and IF, have allowed for significant contributions to AD research. For instance, the involvement of microglia and astrocytes in AD pathogenesis was discovered using IHC microscopy [7] and the pathology of amyloid-β plaques and neuron death was further elucidated via IF microscopy [8] (Figure 1).

Despite the progression of these various microscopy technologies, they are still limited by only being able to simultaneously visualize a small number of target genes or antigens. This is because the fluorophores and enzyme reporters that are used in current IHC protocols show spatial and specie...
High-dimensional multiplexed imaging technology has the capacity to overlay multiple images with different biomarkers for simultaneous analysis and spatial localization. One example of this technology is MIBI-TOF (Figure 1). A recent study published in Cell by Keren et al. (2018) highlighted MIBI-TOF technology within the application of breast cancer pathobiology. This work built on a previous MIBI platform by adding TOF mass spectrometry, which allowed for increased channel multiplexing while decreasing times for data acquisition by 50-fold. With this improved technology, researchers simultaneously analyzed the sub-cellular expression and spatial arrangement of 36 proteins, effectively illuminating the tumor-immune microenvironment. Researchers at Stanford have also used MIBI-TOF to analyze post-mortem brain samples of AD. In addition to validating previously defined AD pathologies, such as taupathy, they were also able to analyze immune cell infiltration, cellular anatomy, and gene expression associated with AD. This is an improvement to previous imaging techniques in AD research as MIBI-TOF can now simultaneously determine the tissue, immunological, and sub-cellular spatial localization of the human brain. While MIBI-TOF has great potential, it is also limited in a number of ways. Firstly, there are a very few available units at this time as the technology has only recently become commercially available. Secondly, MIBI-TOF poses a high cost of reagents (e.g., metal-tagged antibodies), technical experiments, and quality control. Lastly, since MIBI-TOF generates highly dimensional data, researchers must have computational expertise to use the platform effectively. As a result, MIBI-TOF is currently a much less accessible research tool compared to less expensive, simpler technologies such as IHC staining visualized with LM.

**Future Directions and Conclusion**

As new research has shown that AD pathogenesis is characterized by the complex interaction of multiple glial cells and their unique phenotypes, the advent of MIBI-TOF provides the capacity to elucidate these cellular interactions and provide insights into new biomarkers and potential therapeutic avenues. Indeed, MIBI-TOF technology has the potential to revolutionize neuroimaging in AD research. As this technology continues to be used throughout AD research, its true potential will be realized.

---

**Historical Timeline**

| Year | Event |
|------|-------|
| 1858 | Light Microscopy: Virchow, discovered new neural cell type ‘neuroglia’ |
| 1913 | Chloride-Sublimate Stain: Ramón y Cajal, new technique for staining GFAP expressed on astrocytes |
| 1989 | Immunohistochemistry: Hagaki et al., seminal research linking pathology of microglia and astrocytes to AD |
| 2018 | MIBI-TOF: Keren et al., spatial localization with simultaneous subcellular analysis of 30+ targets |
| 1907 | Light Microscopy: Alzheimer, discovered pathologies in dementia patient now associated with AD |
| 1921 | Silver Carbonate Stain: del Rio Hortega, definitely described microglia |
| 2003 | Immunofluorescence: Kayed et al., discovered pathologies in dementia patient now associated with AD |
| 2014 | MIBI: Angelo et al., potential for spatial localization with subcellular analysis |

Figure 1: Historical timeline highlighting the various imaging technologies and staining techniques that have ultimately contributed to the current understanding of the role of glial cells in AD pathology. MIBI time-of-flight (TOF) is seen in the timeline near the present day as it has the potential to revolutionize neuroimaging in AD research.
REFERENCES

[1] Patterson C. World Alzheimer Report 2018. The state of the art of dementia research: New frontiers; Available from: https://www.alz.co.uk/research/world-report-2018.

[2] Chambers LW, Bancej C, McDowell I. Prevalence and monetary costs of dementia in Canada: population health expert panel. Alzheimer Society of Canada in collaboration with the Public Health Agency . . . ; 2016.

[3] Henstridge CM, Hyman BT, Spires-Jones TL. Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis. Nature Reviews Neuroscience. 2019;p. 1.

[4] Somjen GG. Nervenkitt: notes on the history of the concept of neuroglia. Glia. 1988;1(1):2–9.

[5] Stelzmann RA, Norman Schnitzlein H, Reed Murtagh F. An English translation of Alzheimer’s 1907 paper, “Über eine eigenartige Erkankung der Hirnrinde”. Clinical Anatomy: The Official Journal of the American Association of Clinical Anatomists and the British Association of Clinical Anatomists. 1995;8(6):429–431.

[6] Sanderson MJ, Smith I, Parker I, Bootman MD. Fluorescence microscopy. Cold Spring Harbor Protocols. 2014;2014(10):pdb--top071705.

[7] Itagaki S, McGeer P, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. Journal of neuroimmunology. 1989;24(3):173–182.

[8] Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300(5618):486–489.

[9] Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018;174(6):1373–1387.

[10] Oliveria JP, Vijayaragavan K, Bossé M, Tebaykin D, Montine TJ, Angelo M, et al. Multiplexed ion beam imaging (MIBI) produces data-rich images of archival human brains with synaptic resolution. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. 2018;14(7):P700–P701.

Dunavan Morris-Janzen will receive his Bachelor of Arts and Science (Honours) from McMaster University in April 2019. During his undergraduate degree, his research interests were broadly set in immunology. In his final year under the supervision of Dr. John Paul Oliveria, he focused on the role of glial cells in Alzheimer’s Disease pathology and the potential of Multiplexed Ion Beam Imaging technologies for studying these cells.

John Paul Oliveria received his PhD in 2017 and is currently an Adjunct Faculty Member at McMaster University in the Faculty of Health Sciences, Department of Medicine, where he supervises students completing projects and theses within the fields of allergy, immunology, and neurosciences. He is currently completing his post-doctoral fellowship at Stanford University where he is utilizing multiplexed ion beam imaging (MIBI) to unravel cellular and sub-cellular interactions in the brain to understand Alzheimer’s disease. His research interests leverages novel technologies and high dimensional data to discover novel mechanisms in health and disease.